Skip to content

Neck surgery was linked to fewer recurrences in early oral cancer

A review comparing elective neck dissection with observation favored surgery for regional recurrence, while missing follow-up and outcome definitions limit interpretation.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

Elective neck dissection was associated with fewer regional lymph-node recurrences than observation in this review. The authors also reported better overall and disease-specific survival, but the abstract does not clearly describe how the overall-survival risk ratio was coded. These results concern the specified early oral-cancer population and do not establish outcomes for other cancers.

Keep in mind

This abstract-based account lacks follow-up lengths, included study designs and absolute event rates. The abstract also omits treatment harms, limiting assessment of the overall trade-off.

THE NUMBERS, WITH CONTEXT

What researchers found

0.47 times the risk (RR; 95% confidence interval: 0.28–0.77)

Regional nodal recurrence

Elective neck dissection versus observation; a relative comparison, not an absolute risk reduction. Follow-up duration was not reported.

Crit Rev Oncol Hematol, 2026 · Original source ↓

The clinical decision

The question was whether to operate on neck lymph nodes when an early oral cancer has no clinically apparent nodal involvement, or to observe. The review pooled studies comparing these strategies.

Reading the result

Recurrence and survival are separate outcomes. The recurrence estimate favors surgery on a relative-risk scale, but without absolute event rates it cannot show how many patients might avoid a recurrence.

CHECK THE ORIGINAL

The original publication

Impact of elective cervical dissection on the prognosis of patients with oral squamous cell carcinoma cT1/T2N0: A systematic review and meta-analysis.

Binda NC, Lavareze L, Vieira GS et al.
Crit Rev Oncol Hematol · 2026

PubMed ID
41115617
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.